Objectives This study sought to investigate clinical outcomes associated with left atrial
appendage occlusion (LAAO) versus direct oral anticoagulants (DOACs) in patients with …

Abstract Background The PRAGUE-17 (Left Atrial Appendage Closure vs Novel
Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage …

Background Percutaneous left atrial appendage closure (LAAC) is noninferior to vitamin K
antagonists (VKAs) for preventing atrial fibrillation (AF)–related stroke. However, direct oral …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in
clinical practice. One of its most devastating complications is the development of …

Background The optimal antithrombotic therapy following left atrial appendage occlusion
(LAAO) in patients with nonvalvular atrial fibrillation (AF) remains uncertain. Objectives In …

Atrial fibrillation (AF) is a worldwide epidemic associated with significant morbidity and
mortality, often due to disabling or fatal thromboembolic stroke. Oral anticoagulation is highly …

Abstract Aims The PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic
Protection in Patients with Atrial Fibrillation) trial found left atrial appendage (LAA) closure …

Background Atrial fibrillation (AF), with a prevalence of 1% to 2%, is the most common
cardiac arrhythmia. Without antithrombotic treatment, the annual risk of a cardioembolic …

Background: The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic
therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in …

Background: Left atrial appendage (LAA) occlusion provides an alternative to oral
anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial …